MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.

OBJECTIVE The objective of our study was to determine the accuracy of preoperative measurements for detecting pathologic complete response (CR) and assessing residual disease after neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer. SUBJECTS AND METHODS The American College of Radiology Imaging Network 6657 Trial prospectively enrolled women with ≥ 3 cm invasive breast cancer receiving NACT. Preoperative measurements of residual disease included longest diameter by mammography, MRI, and clinical examination and functional volume on MRI. The accuracy of preoperative measurements for detecting pathologic CR and the association with final pathology size were assessed for all lesions, separately for single masses and nonmass enhancements (NMEs), multiple masses, and lesions without ductal carcinoma in situ (DCIS). RESULTS In the 138 women with all four preoperative measures, longest diameter by MRI showed the highest accuracy for detecting pathologic CR for all lesions and NME (AUC = 0.76 and 0.84, respectively). There was little difference across preoperative measurements in the accuracy of detecting pathologic CR for single masses (AUC = 0.69-0.72). Longest diameter by MRI and longest diameter by clinical examination showed moderate ability for detecting pathologic CR for multiple masses (AUC = 0.78 and 0.74), and longest diameter by MRI and longest diameter by mammography showed moderate ability for detecting pathologic CR for tumors without DCIS (AUC = 0.74 and 0.71). In subjects with residual disease, longest diameter by MRI exhibited the strongest association with pathology size for all lesions and single masses (r = 0.33 and 0.47). Associations between preoperative measures and pathology results were not significantly influenced by tumor subtype or mammographic density. CONCLUSION Our results indicate that measurement of longest diameter by MRI is more accurate than by mammography and clinical examination for preoperative assessment of tumor residua after NACT and may improve surgical planning.

[1]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  John Kornak,et al.  Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. , 2014, Translational oncology.

[3]  Samuel J. Magny,et al.  Breast Imaging Reporting and Data System , 2020, Definitions.

[4]  A. Stuckey,et al.  ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. , 2017, Journal of the American College of Radiology : JACR.

[5]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[6]  Nola Hylton,et al.  Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2013, Annals of Surgical Oncology.

[7]  G J Metzger,et al.  MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.

[8]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Akiyama,et al.  MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes , 2011, Breast cancer.

[11]  A. Soran,et al.  MRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy? , 2011, Annals of Surgical Oncology.

[12]  J. Ahn,et al.  Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: Relation to response patterns on MRI , 2007, Acta oncologica.

[13]  L. Esserman,et al.  Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.

[14]  G. Hortobagyi,et al.  Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. , 2001, Cancer journal.

[15]  N. Hylton,et al.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer , 2013, Cancer.

[16]  D. Noh,et al.  Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. , 2012, European journal of radiology.

[17]  Rebecca S Lewis,et al.  Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. , 2004, Radiology.

[18]  Martine Meunier,et al.  Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. , 2007, International journal of radiation oncology, biology, physics.

[19]  Hon J. Yu,et al.  Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. , 2011, Radiology.

[20]  B. Dunn,et al.  The Role of Tamoxifen in Breast Cancer Prevention , 2001, Annals of the New York Academy of Sciences.

[21]  S. Lipsitz,et al.  Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? , 2007, Journal of surgical oncology.

[22]  Yeon-Hee Park,et al.  Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer , 2013, Annals of Surgical Oncology.

[23]  Title Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer : Translational breast cancer research consortium trial , 2022 .

[24]  L. Irwig,et al.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis , 2015, BMC Cancer.

[25]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[27]  S. Vinnicombe,et al.  Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer , 2008, British Journal of Cancer.

[28]  M. Su Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017 , 2013 .

[29]  M. Dieci,et al.  Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II–III Breast Cancer , 2011, Annals of Surgical Oncology.

[30]  J. Gornbein,et al.  Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy , 2009, Cancer.

[31]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[32]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[33]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Fitzgerald,et al.  Optimal assessment of residual disease after neo‐adjuvant therapy for locally advanced and inflammatory breast cancer—clinical examination, mammography, or magnetic resonance imaging? , 2010, Journal of surgical oncology.

[35]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[36]  Ying Lu,et al.  Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.

[37]  S. Ciatto,et al.  Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy , 2013, British Journal of Cancer.

[38]  S. Harms,et al.  Technical Report of the International Working Group on Breast MRI , 1999, Journal of magnetic resonance imaging : JMRI.

[39]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[40]  D. Noh,et al.  Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.